Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEvaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
European Journal of Internal Medicine , 11/06/09
Boehm A et al. – Rapamycin at 2mg per day acts mildly cytoreductive in a subgroup of patients with refractory AML. Higher doses and drug combinations may be required to obtain long lasting anti–leukemic effects in these patients.
Related Articles
Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients
Journal of Dermatological Science, 10/06/09
Relevance Score: 91%
Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs
Nephrology Dialysis Transplantation, 11/17/09
Relevance Score: 89%
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
International Journal of Cancer, 11/10/09
Relevance Score: 88%
MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E–Binding Protein 1–Mediated Inhibition of Autophagy
Cancer Research, 10/06/09
Relevance Score: 87%
Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
Pediatric Blood & Cancer, 10/30/09
Relevance Score: 83%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Sponsor
Article Search
Sponsor